FENC — FENNEC PHARMACEUTICALS INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1211583 ·
Last close
$9.00
Market Cap
$312.63M
52W High
$10.45
52W Low
$5.65
ADV30
330,743
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 15,108,000 | 14,538,000 | -119,000 | 201,000 | 71,822,000 | 40,179,000 | 34,147,000 |
| Dec 2025 | 13,777,000 | 12,013,000 | -2,580,000 | -4,787,000 | 70,551,000 | 36,788,000 | 35,079,000 |
| Sep 2025 | 12,462,000 | 11,802,000 | -201,000 | -638,000 | 49,261,000 | 21,947,000 | 53,753,000 |
| Jun 2025 | 9,652,000 | 8,685,000 | -2,732,000 | -3,152,000 | 44,876,000 | 18,705,000 | 52,339,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,776,000
Investing CF
—
Financing CF
$23,280,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.29
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-229,221,000
Inventory
$1,856,000
Receivables
$18,762,000
ST Investments
—
EBIT TTM
$-6,775,000
Pretax Income TTM
$-8,270,000
Interest Exp TTM
$1,495,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$50,999,000
EBITDA
$-5,490,333
Free Cash Flow
$-2,370,875
Enterprise Value
$272,454,272
Total Cash
$40,179,000
Total Debt
$0
Shares Out
34,737,030
Trailing EPS
$-0.29
Book Value
$1.09
ROE
-52.7%
ROA
-5.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 44,642,000 | -6,346,000 | -9,741,000 | 70,551,000 | — | — | -12,473,000 |
| Dec 2024 | 47,538,000 | 2,479,000 | -436,000 | 44,946,000 | — | — | 26,980,000 |
| Dec 2023 | 21,252,000 | -13,058,000 | -16,045,000 | 26,864,000 | — | — | -17,143,000 |
| Dec 2022 | 1,535,000 | -22,738,000 | -23,714,000 | 26,939,000 | — | — | -18,058,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.89
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $9.19 · call volume: 24 · put volume: 455
Expected Move to 2026-11-20:
±$4.85
(52.77%) —
implied range
$4.34 –
$14.04
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LCTX | Lineage Cell Therapeutics, Inc. | $316.61M | $1.27 | — |
| PALI | PALISADE BIO, INC. | $296.82M | $1.71 | — |
| NMRA | Neumora Therapeutics, Inc. | $329.81M | $1.78 | — |
| PROK | PROKIDNEY CORP. | $336.53M | $1.64 | — |
| LXEO | Lexeo Therapeutics, Inc. | $343.14M | $4.37 | — |
News headlines (Yahoo Finance, 1h cache)
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-06-15 10:00 · Yahoo
Fennec Announces Results of Annual Meeting
2026-06-10 20:30 · Yahoo
Insider Favorites High Growth Companies June 2026
2026-06-08 11:35 · Yahoo
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter
2026-05-23 14:05 · Yahoo
Fennec Announces New Research Supporting Pedmark's Use at ASCO Annual Meeting
2026-05-22 11:21 · Yahoo
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
2026-05-21 22:01 · Yahoo
Fennec Pharmaceuticals Inc (FENC) Q1 2026 Earnings Call Highlights: Record Sales Surge and ...
2026-05-14 23:03 · Yahoo
Fennec Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
2026-05-14 21:11 · Yahoo
Do Options Traders Know Something About Adherex Technologies Stock We Don't?
2026-05-14 15:32 · Yahoo
Adherex Technologies Q1 Earnings Call Highlights
2026-05-14 15:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.